Clinical Trial Update: Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab in relapsed or refractory mycosis fungoides or Sezary syndrome completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides
• Sezary Syndrome

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2019-02-05